Abstract:In order to discover antiplatelet drugs with novel structures and expand our research scope, total twenty 1,3-benzenedisulfonyl piperazines, were designed and synthesized. These target compounds were divided into two series, namely 4-methoxy-1,3-benzenedisulfonyl piperazines of series 1 and 4-ethoxy-1,3-benzenedisulfonyl piperazines of series 2. With adenosine diphosphate (ADP), arachidonic acid (AA) and collagen as inducers, respectively, the Born turbidimetric method was used to screen the anti-platelet activity in vitro of all target compounds at a concentration of 1.3 μM, aspirin and picotamide as positive control drugs. And of which, the activity of five compounds for collagen was higher than both picotamide and aspirin. In ADP or AA channel, compounds with an inhibition rate greater than 33% were selected, and their corresponding IC50 values were obtained. According to the IC50, the in vitro activity of one compound for ADP was higher than picotamide, and for AA, two compounds were higher than two positive control drugs and other two compounds only higher than or equal to aspirin. Completed the preliminary analysis of the structure-activity relationship of the compound involved in this study. Further, eight compounds exhibiting the high activity in one or two test channels, were subjected to cytotoxicity test on mouse fibroblasts (L929) by CCK-8 method. The in vitro cytotoxicity of most test compounds showed less than or same to control drug picotamide at 10 μM, but at the higher concentration of 100 μM, merely two compounds exhibited higher cell survival rate than that of picotamide. In addition, compound N1, N3-di (4-ethoxy-1, 3-benzenedisulfonyl)bis(1-(m-tolyl)piperazine), which is delivery activity in the three test channels, and compound N1, N3- di (4-methoxy-1, 3-phenylenedisulfonyl)bis(1-(m-tolyl)piperazine), which is the lowest cytotoxic in vitro compound among series 1 and series 2, respectively, are found and selected for simulation analysis as two most likely to dock with the receptor P2Y12. Each of synthesized compounds in silico molecular property and ADME (absorption, distribution, metabolism and excretion) are predicted by using Molinspiration property engine v2018.10 and PreADMET online servers, respectively. Compared with other series of compounds in the previous stage, the two series compounds obtained after the introduction of piperazinyl have a similar in vitro activity.

Synthesis and Anti-platelet Aggregation Activities of Novel N-substituted-tetrahydrothieno [3,2-C] Pyridine Derivatives

Synthesis and Antiplatelet Aggregation Activity of Dihydropyridazinone Derivatives

Synthesis and the Antiplatelet Aggregative Activity of 4,5-Di-hydro-3 (2 H)-pyridazinones

Synthesis and Antiplatelet Activities of N-Arylmethyl-3,4-dimethylpyrano(2,3-c)pyrazol-6-one Derivatives.

Synthesis and Antithrombotic Activity of 3-Aryl-1,2,3,4-oxatriazole-5-imine-coupled Aspirin

Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents

Synthesis and platelet aggregation inhibition activity of new derivatives of pyridazinone

Synthesis of Pyridazinone Derivatives and Study of Their Antiplatelet Aggregation Activity

Synthesis and biological evaluation of N 6 derivatives of 8-azapurine as novel antiplatelet agents

Novel Synthesis Approach and Antiplatelet Activity Evaluation of 6-Alkylamino-2,4-dialkyl(aryl)thiopyrimidines

Synthesis and Biological Evaluation of N6 Derivatives of 8-Azapurine As Novel Antiplatelet Agents

Design, Synthesis and Evaluation of 1,4-Benzodioxine Derivatives As Novel Platelet Aggregation Inhibitors.

Synthesis and Antiplatelet Aggregative Activity of 6-[4-(substituted Amino Acet-Amido-phenyl)]-4,5-dihydro-3(2 H)-pyridazinones

Design, Synthesis, and Biological Evaluation of 2-(Phenoxyaryl)-3-urea Derivatives As Novel P2Y1 Receptor Antagonists

Synthesis, Resolution, and Antiplatelet Activity of 3-Substituted 1(3H)-Isobenzofuranone.

Synthesis and antiplatelet aggregation activities of prasugrel derivatives

Design, Synthesis and Antithrombotic Evaluation of Novel Non-Peptide Thrombin Inhibitors.

Synthesis, Preliminary Structure-Activity Relationships, and in Vitro Biological Evaluation of 6-Aryl-3-amino-thieno[2,3-b]pyridine Derivatives As Potential Anti-Inflammatory Agents.

Synthesis of N-6-Alkyl(Aryl)-2-Alkyl(Aryl)Thioadenosines As Antiplatelet Agents

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Synthesis and Biological Evaluation of Ticagrelor Derivatives As Novel Antiplatelet Agents.